Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases

NCT01934894 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped Study was terminated due to lack of significant signal of efficacy

Conditions

Metastatic Breast Cancer With Intracranial Metastases

Interventions

DRUG: cabazitaxel
DRUG: lapatinib

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]
[object Object]
[object Object]